Eli Lilly and Boehringer Ingelheim established a broad diabetes alliance to jointly develop and commercialize a portfolio of diabetes compounds, anchored by empagliflozin (Jardiance), an SGLT2 inhibitor, and linagliptin (Tradjenta), a DPP-4 inhibitor. The alliance structure involves 50/50 cost and revenue sharing globally. BI contributes the compounds and Lilly contributes its diabetes commercial infrastructure. Financial terms were not fully disclosed but the combined portfolio has generated over $10B in annual revenue.